HP
RNAM

HealthInvest Partners’s Avidity Biosciences RNAM Stock Holding History

HealthInvest Partners’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,978
Closed -$240K – 45
2025
Q3 		$240K Buy
+51,978
New +$2.1M 0.89% 31

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HealthInvest Partners's RNAM Position: Q4 2025 in Review

HealthInvest Partners sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 51,978 shares — an estimated $240K sold.

HealthInvest Partners first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $240K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • HealthInvest Partners reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • HealthInvest Partners sold 51,978 Avidity Biosciences shares in Q4 2025, an estimated $240K.
  • HealthInvest Partners first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
  • HealthInvest Partners's Avidity Biosciences position peaked at $240K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on HealthInvest Partners's 13F filing for Q4 2025, filed 6 Feb 2026.